There are several main indicators in place when considering MultiCell as a potential investment. First of all, this is a clinical-stage biopharmaceutical company with three subsidiaries developing cell-based assay systems for use in drug discovery, as well as for addressing unmet medical needs for the treatment of neurological disorders and cancer. Since there is no product to market yet, the company has no revenues, only mounting liabilities. There are already recognitions for MultiCell`s efforts as well. Last November, the company received a $730k cash grant award from the U.S. Government Qualifying Therapeutic Discovery Project Program. Last but not least, the company is in the final stages of testing its products. If the results are positive and approvals from the respective authorities are granted, marketing and sales can start. [BANNER]
All these points have to be considered when looking at this stock. There is also one more fact to consider, though. This is whether an investor is willing to risk losing his entire investment. Because for MultiCell it is not government grants or positive news about product development that drive the stock price up. It is speculations, and they tend to suit only the short-term investors, leaving most of the other traders with huge losses and regret that they ever got involved in a company with such uncertain future.
